

Simvastatin (Flolipid®, Zocor®)

Simvastatin (Flolipid®, Zocor®) belongs to a class of medications called statins. It is used to lower cholesterol levels and to reduce the risk for heart attack, stroke, and other heart problems.

Jamie, based on your genetic result, your body is likely to have a typical response to simvastatin (Flolipid®, Zocor®).

This means that based on the DNA variant we tested, simvastatin (Flolipid®, Zocor®) is likely to work as expected for you. However, other factors – such as having a DNA variant not included in this test, certain health conditions, or taking other medications – may influence your response. **Do not use this result to start, stop, or change any course of treatment.** Medications should always be taken as directed.

Likely typical response

to simvastatin (Flolipid®, Zocor®)

→ [Learn more about your result](#)

Keep in mind



If you are already taking this medication, **continue your treatment as directed** unless your doctor recommends a change.



Other factors besides your genetics can also affect your body's response to this medication.



This test **does not include all possible DNA variants** that may affect your body's response to this medication.



This result **does not apply to** all cholesterol-lowering medications.

About simvastatin

Also known as: Flolipid®¹, Zocor®²; and in combination products known as Simcor®³ and Vytorin®⁴



Primary uses of this medication

Simvastatin is a cholesterol-lowering medicine (statin). It is used along with diet to reduce bad cholesterol (low-density lipoprotein cholesterol, LDL-C) in adults with hyperlipidemia and in adults and children aged 10 years and older with a genetic condition called heterozygous familial hypercholesterolemia. It is used in adults with primary dysbetalipoproteinemia (a condition that causes high levels of cholesterol and fat in the blood), hypertriglyceridemia, and homozygous familial hypercholesterolemia. It is used to reduce the risk of heart attack, stroke, certain types of heart and blood vessel surgery, and death from heart disease in adults with heart disease or at high risk of developing heart disease.



How this medication works

Simvastatin reduces the amount of cholesterol in the bloodstream by blocking an enzyme called HMG-CoA reductase that the liver uses to make cholesterol. This reduction in cholesterol levels can help prevent cholesterol from building up on the walls of blood vessels, which can help reduce the risk of heart attack and stroke.

Read more at: [MedlinePlus](#)⁵ [DailyMed](#)⁶

Share a summary of your Pharmacogenetics reports with a healthcare professional.

If you ever need treatment with simvastatin, a healthcare professional like your doctor or pharmacist may be able to use this report for reference.

Do not use this result to start, stop, or change any course of treatment. Medications should always be taken as directed.



Print summary

Your Genetic Result

SLCO1B1 Drug Transport

Predicted normal function



[View report >](#)

References

- Carr DF et al. (2013). "SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink." *Clin Pharmacol Ther.* 94(6):695-701. ¹
- Caudle KE et al. (2017). "Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)." *Genet Med.* 19(2):215-223. ²
- Cooper-DeHoff RM et al. (2022). "The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms." *Clin Pharmacol Ther.* 111(5):1007-1021. ³
- Danik JS et al. (2013). "Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy." *Am Heart J.* 165(6):1008-14. ⁴
- Donnelly LA et al. (2011). "Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: A go-DARTS study." *Clin Pharmacol Ther.* 89(2):210-6. ⁵
- Hopewell JC et al. (2020). "Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom." *Eur Heart J.* 41(35):3336-3342. ⁶
- Li JH et al. (2014). "Genetically guided statin therapy on statin perceptions, adherence, and cholesterol lowering: a pilot implementation study in primary care patients." *J Pers Med.* 4(2):147-62. ⁷
- Nielsen SF et al. (2016). "Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study." *Eur Heart J.* 37(11):908-916. ⁸
- Pasanen MK et al. (2006). "SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid." *Pharmacogenet Genomics.* 16(12):873-9. ⁹
- Peysers B et al. (2018). "Effects of delivering SLCO1B1 pharmacogenetic information in randomized trial and observational settings." *Circ Genom Precis Med.* 11(9):e002228. ¹⁰
- Pittman DG et al. (2011). "Adherence to statins, subsequent healthcare costs, and cardiovascular hospitalizations." *Am J Cardiol.* 107(11):1662-6. ¹¹
- SEARCH Collaborative Group et al. (2008). "SLCO1B1 variants and statin-induced myopathy—a genome-wide study." *N Engl J Med.* 359(8):789-99. ¹²
- Turongkaravee S et al. (2021). "A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy." *Pharmacogenomics J.* 21(3):296-307. ¹³
- Turner RM et al. (2020). "A genome-wide association study of circulating levels of atorvastatin and its major metabolites." *Clin Pharmacol Ther.* 108(2):287-97. ¹⁴
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research. "Flolipid® (simvastatin) NDA 206679 label." Retrieved August 30, 2021 from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206679s003lbl.pdf ¹⁵
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research. "Zocor® (simvastatin) NDA 019766 label." Retrieved August 12, 2021 from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/019766s101lbl.pdf ¹⁶
- U.S. Food and Drug Administration (2021). "Table of Pharmacogenetic Associations." Retrieved February 24, 2023 from <https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations> ¹⁷
- Vassy JL et al. (2020). "Effect of Pharmacogenetic Testing for Statin Myopathy Risk vs Usual Care on Blood Cholesterol: A Randomized Clinical Trial." *JAMA Netw Open.* 3(12):e2027092. ¹⁸
- Voora D et al. (2009). "The SLCO1B1*5 genetic variant is associated with statin-induced side effects." *J Am Coll Cardiol.* 54(17):1609-16. ¹⁹
- Ward NC et al. (2019). "Statin Toxicity." *Circ Res.* 124(2):328-350. ²⁰

Change Log

Your report may occasionally be updated based on new information. This Change Log describes updates and revisions to this report.

Date	Change
July 19, 2023	Simvastatin (Flolipid®, Zocor®) report created.

¹Flolipid® is a registered trademark of Salerno Pharmaceuticals LP; ²Zocor® is a registered trademark of Merck & Co., Inc.; ³Simcor® is a registered trademark of Kos Pharmaceuticals, Inc.; ⁴Vytorin® is a registered trademark of MSP Singapore Company, LLC



Give the gift of DNA discovery.

Gift a kit

Earn up to \$20 for each friend you refer.

Get \$20

ANCESTRY

Ancestry Overview
All Ancestry Reports
Ancestry Composition
DNA Relatives
Order Your DNA Book

HEALTH & TRAITS

Health & Traits Overview
All Health & Traits Reports
My Health Action Plan
Health Predisposition
Pharmacogenetics
Carrier Status
Wellness
Traits

RESEARCH

Research Overview
Surveys and Studies
Edit Answers
Publications

FAMILY & FRIENDS

View all DNA Relatives
Family Tree
Your Connections
GrandTree
Advanced DNA Comparison